Angiogenesis

UCLA Researchers Test Cancer Drug on Humans

Published in Vaccine Weekly, May 18th, 1998

A potential treatment for cancer that kills tumors by starving them of their blood supply is being tested on humans by doctors at the University of California at Los Angeles (UCLA), researchers reported.

The drug has been in Phase I trials on 30 patients at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles since September 1997.

Called SU5416, the drug developed by Sugen Inc., Redwood City, California, is an angiogenesis inhibitor, which like other recently publicized treatments, completely wiped out tumors in mice, they said.

Competing angiogenesis inhibitor drugs from EntreMed Inc., angiostatin...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1998-05-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry